Granted Patent
B2
US 11,904,022 · App. 17/213,750 · Granted Feb 20, 2024
Carrier-free curcumin nanoparticle for EGFR positive cancer therapy
Assignee:
UNIVERSITY OF SOUTH CAROLINA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A carrier-free nanoparticle based on the self-assembly of curcumin-erlotinib conjugate (EPC) that exhibits stronger cell killing, better anti-migration effects, and anti-invasion effects for pancreatic cancer cells than the combination of free curcumin and erlotinib.
Claims (5)
1. A method for preparing a carrier-free nanoparticle for tumor growth inhibition comprising:
synthesizing PEG modified erlotinib;
conjugating the PEG modified erlotinib with curcumin to form an erlotinib-curcumin conjugate;
dissolving the erlotinib-curcumin conjugate in acetone to form a solution; and
adding the solution dropwise to deionized water to self-assemble at least one nanoparticle.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 26, 2021
From: XU, PEISHENG
To: UNIVERSITY OF SOUTH CAROLINA
Reel/Frame 055732/0666 →
Continuity (2)
Provisional Application
63029782
· May 26, 2020